CCTV: Tasly Accelerates Its Drug Research and Development to Build a Line of Defense for Health

CCTV: Tasly Accelerates Its Drug Research and Development to Build a Line of Defense for Health

For a long time, diseases such as cardiovascular diseases and oncology and autoimmune diseases have seriously threatened the safety and health of human beings, and have shown a trend of high incidence and occurrence in younger groups. Tasly, as one of the companies selected by the CCTV Brand Power Project, is continuously accelerating the research and development of innovative drugs, and building a line of defense for life and health with the achievement in innovative scientific research.  

On May 27, the “Economic News” of CCTV-2 reported this.

As covered by CCTV in the report, as a subsidiary of Tasly, Tasly Biopharma has independently developed Category I Major Innovative Biologic Drug PUK, whose acute ischemic stroke indication Phase III clinical trial and acute pulmonary embolism Phase II clinical trial have completed the enrollment, and it is expected to submit a new drug application this year.

PUK, which is the only approved recombinant human prourokinase product in China, was included in the “Catalog of Medicines” covered by National Medical Insurance System twice in 2017 and 2019. We believe that PUK has huge potential to become a blockbuster thrombolytic drug in China.

Yan Kaijing, the executive Chairman of the Board of Tasly Holding Group and chairman of Tasly Pharmaceutical Group, said that in recent years, It has increased investment in the research and development of innovative drugs and integrated global advanced technologies, including gene networks, artificial intelligence, biomedicine and big data, to accelerate the commercialization of innovative results and serve the majority of patients.